The three CDK4/6 inhibitors are used in estrogen receptor (ER)-positive breast cancer based on clinical trials demonstrating improved progression-free survival when combined with antiestrogen therapy, the golden standard for treatment of ER-positive disease [33,34,35]. This evidence concerns the gene ESR1 and breast carcinoma.